Two of the most widely available medicines for dementia in the UK are cholinesterase inhibitors and a N-methyl-D-aspartate (NMDA) receptor antagonists (NHS, 2013).  Both drugs are popular because they have been found to lead to improvements in dementia symptoms (Raina 2008). However, some have raised concerns about the safety for patients. These concerns are partly [read the full story…]